Making the cut: Untangling clinical protein biomarker discovery and validation

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 189-191

  Gold, Larry ^a   Williams, Stephen ^a   Janjic, Nebojsa ^a   Saccomano, Nick ^a   Steele, Fintan ^a,b  

^a SomaLogic Inc   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

aptamers; biomarker; personalized medicine; proteomics; SOMAmers

Indexed keywords

APTAMER; BIOLOGICAL MARKER; PROTEIN; SLOW OFF RATE MODIFIED APTAMER; UNCLASSIFIED DRUG;

DNA MICROARRAY; EDITORIAL; GENOMICS; HUMAN; PERSONALIZED MEDICINE; PROTEIN BINDING; PROTEOMICS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

APTAMERS, PEPTIDE; BIOLOGICAL MARKERS; HUMANS; PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 79953907751     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.11     Document Type: Editorial

References (12)

1. Mitchell P: Proteomics retrenches. Nat Biotechnol. 28(7), 665-670 (2010).
2. Collins F: Has the revolution arrived? Nature 464(7289), 674-675 (2010).
3. Hirschorn JN, Gaidos ZK: Genome-wide association studies: results from the frst few years and potential implications for clinical medicine. Annu. Rev. Med. 62, 11-24 (2011).
4. Aebersold R, Anderson L, Caprioli R et al.: Perspective: a program to improve protein biomarker discovery for cancer. J. Proteome. Res. 4(4), 1104-1109 (2005). (Pubitemid 41208668)
5. Mallick P, Kuster B: Proteomics: a pragmatic perspective. Nat. Biotechnol. 28(7), 695-709 (2010).
6. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968), 505-510 (1990).
7. Vaught JD, Bock C, Carter J et al.: Expanding the Chemistry of DNA for in vitro Selection. J. Am. Chem. Soc 132(12), 4141-4151 (2010).
8. Gold L, Ayers D, Bertino J et al.: Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12), e15004 (2010).
9. Keeney TR, Bock C, Gold L et al.: Automation of the SomaLogic proteomics assay: a platform for biomarker discovery J. Assoc Lab. Automat. 14, 360-366 (2009).
10. Ostroff RM, Bigbee WL, Franklin W et al.: Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5(12), e15003 (2010).
11. Gupta S, Thirstrup D, Jarvis TC et al.: Rapid histochemistry using slow off-rate modifed aptamers with anionic competition. Appl. Immuno hist o ch em. Mol. Morphol. DOI: 10.1097/PAI.0b013e3182008c29 (2011) (Epub ahead of print).
12. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123-132 (2006).